Is Egrifta (Tesamorelin) Legal in Missouri?

HealthRX.com

Egrifta is FDA-approved, but this page covers federal rules only

Print or save as PDF

Key numbers

  • 5%Share of tesamorelin patients whose HbA1c reached 6.5% or higher by week 26, versus 1% on placeboSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 25%Share of tesamorelin patients with injection-site reactions in the first 26 weeks, versus 14% in the comparison groupSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026
  • 2 mgVial strength of Egrifta SV, one of the two current tesamorelin formulationsSource: dailymed.nlm.nih.gov, as cited Nov 7, 2026

See the public record for Tesamorelin

  • Drug / Tesamorelin, sold as Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial) [2][3]
  • FDA approval / Egrifta first approved November 10, 2010, application BLA 022505 [1]
  • Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
  • Approved dose / Egrifta SV 1.4 mg daily; Egrifta WR 1.28 mg daily; not substitutable [2][3]
  • Compounding lists / In no category of FDA's bulk-substance lists for state-licensed pharmacies or outsourcing facilities [4][5][6]
  • Sport / Prohibited at all times under WADA section S2.2.4 [7]

What the FDA approval covers

FDA approved tesamorelin on November 10, 2010 under application BLA 022505; the application began as an NDA and was deemed a BLA on March 23, 2020 [1]. The current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026, and both once-daily subcutaneous injections [2][3].

The approved use is narrow: reducing excess abdominal fat in HIV-infected adults with lipodystrophy. The label states that long-term cardiovascular safety has not been established, and that the drug is not indicated for weight loss because its effect on weight is neutral [2].

Doses differ between the two products. Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) into the abdomen once daily; Egrifta WR is 1.28 mg (0.16 mL) once daily. The labels state that the two are not substitutable [2][3]. Tesamorelin is a growth hormone-releasing factor analog, not growth hormone: it stimulates pituitary GRF receptors so the pituitary releases the body's own growth hormone, which raises IGF-1 [2].

Compounding status

Tesamorelin is absent from FDA's list of bulk substances that may present significant safety risks when compounded (dated April 22, 2026) and from every category of FDA's bulk-substance list for state-licensed pharmacies and physicians (updated May 14, 2026) and for outsourcing facilities (updated March 21, 2025) [4][5][6]. FDA has made no category-based statement about compounding it [4][5][6]. It is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding, filed October 28, 2026 [8][9]. Absence from those lists is not approval: a compounded drug is not FDA-approved, and FDA does not review a compound's safety, effectiveness or quality before it is marketed [8][9].

Questions worth asking

Choose the questions you want to keep

Athletes: prohibited at all times

WADA names tesamorelin in section S2.2.4, among growth hormone-releasing factors, GHRH and its analogues [7]. It is prohibited at all times, in and out of competition, and S2 substances are non-Specified Substances [7]. It is on the 2026 List and remains on the 2027 List [7][10].

What the label says to watch for

Tesamorelin is contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity to tesamorelin or the excipients, and pregnancy [2][3]. Among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated 52 weeks, 34% and 23% [2]. HbA1c of 6.5% or higher developed in 5% versus 1% on placebo by week 26, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6) [2]. Injection-site reactions occurred in 25% versus 14% during the first 26 weeks [2].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. What once-daily dose does the article give for Egrifta WR?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Is Egrifta (tesamorelin) legal in Missouri?
Egrifta is an FDA-approved prescription drug, first approved November 10, 2010. The FDA records on this page are federal and do not set out Missouri-specific rules [1][2][3].
Can a compounding pharmacy make tesamorelin?
FDA's lists do not establish whether a pharmacy may make tesamorelin in Missouri. Tesamorelin is not on FDA's list of bulk substances that may present significant safety risks when compounded, and it appears in no category of the state-licensed pharmacy or outsourcing facility lists, so FDA has made no category-based statement about it [4][5][6]. A compounded version is not an FDA-approved drug [8][9].
Is tesamorelin approved for weight loss?
No. The label states it is not indicated for weight loss management because its effect on weight is neutral; the approved use is excess abdominal fat in HIV-infected adults with lipodystrophy [2].
Is tesamorelin banned in sport?
Yes. WADA's section S2.2.4 names it and prohibits it at all times, in and out of competition [7][10].
What dose do the labels give?
Egrifta SV is 1.4 mg injected subcutaneously into the abdomen once daily; Egrifta WR is 1.28 mg once daily [2][3].
Show all 10 referencesHide references
  1. Drugs@FDA: FDA-Approved Drugs.
  2. U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
  3. U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
  4. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
  5. U.S. Food and Drug Administration.
  6. U.S. Food and Drug Administration.
  7. World Anti-Doping Agency.
  8. Official web page.
  9. Official web page.
  10. World Anti-Doping Agency.
Evidence overview for Is Egrifta (Tesamorelin) Legal in Missouri?